medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-12-98-104medsovet-2571Research ArticleРЕВМАТОЛОГИЯRHEUMATOLOGYТопические формы диклофенака в лечении заболеваний опорно-двигательного аппаратаTopical diclofenac for the treatment of the musculoskeletal diseasesИмаметдиноваГ. Р.ImametdinovaG. R.

к.м.н.

PhD in medicine

ИголкинаЕ. В.IgolkinaE. V.

к.м.н.

PhD in medicine

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», МоскваРоссияFederal budgetary state institution «Scientific research Institute of rheumatology named after V. A. Nasonova», MoscowRussian Federation20182507201801298104Copyright © Имаметдинова Г.Р., Иголкина Е.В., 20182018Имаметдинова Г.Р., Иголкина Е.В.Imametdinova G.R., Igolkina E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2571

Лечение заболеваний опорно-двигательного аппарата до настоящего времени остается не только серьезной медицинской, но и социально-экономической проблемой. Хронические заболевания суставов и позвоночника являются одной из наиболее частых причин инвалидизации пациентов. Основными клиническими проявлениями большинства заболеваний опорно-двигательного аппарата являются боль и воспаление, что требует проведения адекватной противовоспалительной терапии. Представлены данные о многообразных механизмах действия нестероидного противовоспалительного препарата (НПВП) диклофенак (Вольтарен), а также результаты клинических исследований и метаанализов, подтверждающих его эффективность и хорошую переносимость. Представлены данные экспериментальных и клинических исследований эффективности и безопасности локальных форм диклофенака – Вольтарен Эмульгель (диклофенака диэтиламин). Приводятся данные о форме Вольтарен Эмульгель 2% 12 часов. Показано, что широкий спектр анальгетического и  противо воспалительного действия диклофенака (Вольтарен) и хорошая переносимость позволяют использовать его в качестве симптоматической терапии в лечении заболеваний опорно-двигательного аппарата.

 

Treatment of diseases of the musculoskeletal system to date remains not only a serious medical, but also socio-economic problem. Chronic diseases of the joints and spine are one of the most common causes of disability in patients. The main clinical manifestations of most diseases of the musculoskeletal system are pain and inflammation, which requires adequate antiinflammatory therapy. The data on various mechanisms of action of non-steroidal anti-inflammatory drug (NSAID) diclofenac (Voltaren), as well as the results of clinical studies and meta-analyses confirming its effectiveness and good tolerability are presented. The data of experimental and clinical studies of the efficacy and safety of local forms of diclofenac-Voltaren Emulgel (diclofenac-diethylamine) –are presented. Provides information about the form of the Voltaren Emulgel 2% for 12 hours. It is shown that a wide range of analgesic and anti-inflammatory effects of diclofenac (Voltaren), and good tolerance can be used as symptomatic therapy in the treatment of diseases of the musculoskeletal system.

 

нестероидные противовоспалительные препаратызаболевания опорно-двигательного аппаратадиклофенакВольтаренВольтарен Эмульгельnon-steroidal anti-inflammatory drugsdiseases of the musculoskeletal systemdiclofenacVoltarenVoltaren EmulgelReferencesНасонов Е.Л., Яхно Н.Н., Каратеев А.Е. и соавт. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология, 2016, (54) 3: 247-65.Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment of musculoskeletal pain: interdisciplinary consensus. Nauchno-Prakticheskaya Revmatologiya, 2016, (54) 3: 247-65.Верткин А.Л., Алексеева Л.И., Наумов А.В. и др. Остеоартроз в практике врача-терапевта. РМЖ, 2008, 16(7): 33-7.Vertkin AL, Alekseeva LI, Naumov AV. Osteoarthrosis in the practice of a physician. RMJ, 2008, 16 (7): 33-7.van Dijk GM, Veenhof C, Schellevis F, et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMS Musculoscelet Disord, 2008, Jun 26, 9: 95. doi: 10.1186/1471-2474-9-95.van Dijk GM, Veenhof C, Schellevis F, et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMS Musculoscelet Disord, 2008, Jun 26, 9: 95. doi: 10.1186/1471-2474-9-95.Насонов Е.Л. Применение нестероидных противовоспалительных препаратов: терапевтические перспективы. РМЖ, 2002, 4(148): 206.Nasonov EL. The use of non-steroidal anti-inflammatory drugs: therapeutic prospects. RMJ, 2002, 4 (148): 206.Каратеев А.Е., Насонов Е.Л., Яхно Н.Н., Ивашкин В.Т. и соавт. Рациональное использование нестероидных противовоспалительных препаратов (НПВП) в клинической практике. Клинические рекомендации. М., ИМА-Пресс, 2015.Karateev AE, Nasonov EL, Yakhno NN, Ivashkin VT, et al. Rational use of non-steroidal anti-inflammatory drugs (NSAIDs) in clinical practice. Clinical guidelines. IMA-Press, Moscow, 2015.Рациональное использование нестероидных противовоспалительных препаратов. Междисциплинарный консенсус экспертов (основные положения) по результатам совещания группы экспертов 01.04.2017. М., Терапия, 2017, (4): 9-14.Rational use of non-steroidal anti-inflammatory drugs, interdisciplinary consensus of experts (main provisions) following the results of the expert group meeting 01/04/2017. Moscow. Terapiya, 2017, (4): 9-14Crofford LJ, Lipsky PE, Brooks P. et al. Basic biology and clinical application of specific cyclooxigenase-2 inhibitors. Arthritis Rheum, 2000, 43: 4-13.Crofford LJ, Lipsky PE, Brooks P. et al. Basic biology and clinical application of specific cyclooxigenase-2 inhibitors. Arthritis Rheum, 2000, 43: 4-13.Насонова В.А. Вольтарен® (диклофенак натрия) в ревматологии в начале XXI века. РМЖ, 2004, 12(6): 1380-1385.Nasonova VA. Voltaren® (diclofenac sodium) in rheumatology at the beginning of the 21st century. RMJ, 2004, 12 (6): 1380-1385.Насонов Е.Л. Нестероидные противовоспалительные препараты. Москва, 2000.Nasonov EL. Non-steroidal anti-inflammatory drugs. Moscow, 2000.Рациональная фармакотерапия ревматических заболеваний под редакцией В.А. Насоновой, Е.Л. Насонова, 2003.Rational pharmacotherapy of rheumatic diseases edited by Nasonova VА, Nasonova EL, 2003.Рисс В., Крупп П.Й. Фармакокинетика диклофенака у животных и человека. В кн.: Новые возможности клинического применения нестероидных противовоспалительных средств в ревматологии. М., 1976: 19-38.Riss V, Krupp PY. Pharmacokinetics of diclofenac in animals and humans. In the book: New possibilities of the clinical use of non-steroidal anti-inflammatory drugs in rheumatology. M., 1976: 19-38.Насонов Е.Л. Нестероидные противовоспалительные препараты при ревматических заболеваниях: стандарт лечения. РМЖ, 2001, 9(7–8): 265–270.Nasonov EL. Nonsteroidal anti-inflammatory drugs for rheumatic diseases: standard of treatment. RMJ, 2001, 9 (7–8): 265-270.Warner T, Mitchell J. Cyclooхygenases: new forms, new inhibitors, and lesson from the clinic. The Faseb J, 2004, 18: 790–804.Warner T, Mitchell J. Cyclooхygenases: new forms, new inhibitors, and lesson from the clinic. The Faseb J, 2004, 18: 790–804.O’Neill LA, Lewis GP. Inhibitory effects of diclofenac and indomethacin on interleukin-1-induced changes in PGE2 release. A novel effect on free arachidonic acid levels in human syno-vial cells. Biochem Pharmacol, 1989 Nov 1, 38(21): 3707-11.O’Neill LA, Lewis GP. Inhibitory effects of diclofenac and indomethacin on interleukin-1-induced changes in PGE2 release. A novel effect on free arachidonic acid levels in human syno-vial cells. Biochem Pharmacol, 1989 Nov 1, 38(21): 3707-11.Meyer FA, Yaron I, Mashiah V, Yaron M. Effect of diclofenac on prostaglandin E and hyaluronic acid production by human synovial fibroblasts stimulated with interleukin-1. Br J Clin Pharmacol, 1989 Aug, 28(2): 193-6.Meyer FA, Yaron I, Mashiah V, Yaron M. Effect of diclofenac on prostaglandin E and hyaluronic acid production by human synovial fibroblasts stimulated with interleukin-1. Br J Clin Pharmacol, 1989 Aug, 28(2): 193-6.Moilanen E. Effects of diclofenac, indomethacin, tolfenamic acid and hydrocortisone on prostanoid production in healthy and rheumatic synovial cells. Agents Actions, 1989 Mar, 26(3–4): 342-9.Moilanen E. Effects of diclofenac, indomethacin, tolfenamic acid and hydrocortisone on prostanoid production in healthy and rheumatic synovial cells. Agents Actions, 1989 Mar, 26(3–4): 342-9.Giagoudakis G, Markantonis SL. Relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs indomethacin, diclofenac, and ibuprofen. Pharmacotherapy, 2005 Jan, 25(1): 18–25.Giagoudakis G, Markantonis SL. Relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs indomethacin, diclofenac, and ibuprofen. Pharmacotherapy, 2005 Jan, 25(1): 18–25.Martinez LL, Aparecida De Oliveira M, Fortes ZB. Influence of verapamil and diclofenac on leukocyte migration in rats. Hypertension, 1999 Oct, 34(4 Pt 2): 997-1001.Martinez LL, Aparecida De Oliveira M, Fortes ZB. Influence of verapamil and diclofenac on leukocyte migration in rats. Hypertension, 1999 Oct, 34(4 Pt 2): 997-1001.Gonzalez E, de la Cruz C, de Nicolas R, Egido J, Herrero–Beaumont G. Long–term effect of nonsteroidal anti–inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions, 1994 May, 41(3-4): 171-8.Gonzalez E, de la Cruz C, de Nicolas R, Egido J, Herrero–Beaumont G. Long–term effect of nonsteroidal anti–inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions, 1994 May, 41(3-4): 171-8.Bell AL, Adamson H, Kirk F, McCaigue MD, Rotman H. Diclofenac inhibits monocyte super-oxide production ex vivo in rheumatoid arthritis. Rheumatol Int, 1991, 11(1): 27–30.Bell AL, Adamson H, Kirk F, McCaigue MD, Rotman H. Diclofenac inhibits monocyte super-oxide production ex vivo in rheumatoid arthritis. Rheumatol Int, 1991, 11(1): 27–30.Ortiz MI, Granados-Soto V, Castaneda-Hernandez G. The NO-cGMP-K+ channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav, 2003 Aug, 76(1): 187–95.Ortiz MI, Granados-Soto V, Castaneda-Hernandez G. The NO-cGMP-K+ channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav, 2003 Aug, 76(1): 187–95.Bjorkman RL, Hedner T, Hallman KM, Henning M, Hedner J. Localization of the central antinociceptive effects of diclofenac in the rat. Brain Res, 1992 Sep 11, 590(1–2): 66–73.Bjorkman RL, Hedner T, Hallman KM, Henning M, Hedner J. Localization of the central antinociceptive effects of diclofenac in the rat. Brain Res, 1992 Sep 11, 590(1–2): 66–73.Edwards SR, Mather LE. Diclofenac increases the accumulation of kynurenate following tryptophan pretreatment in the rat: a possible factor contributing to its antihyperalgesic effect. Inflammopharmacology. 2003, 11(3): 277–92.Edwards SR, Mather LE. Diclofenac increases the accumulation of kynurenate following tryptophan pretreatment in the rat: a possible factor contributing to its antihyperalgesic effect. Inflammopharmacology. 2003, 11(3): 277–92.Lee HM, Kim HI, Shin YK, Lee CS, Park M, Song JH. Diclofenac inhibition of sodium currents in rat dorsal root ganglion neurons. Brain Res, 2003 Nov 28, 992(1): 120–7.Lee HM, Kim HI, Shin YK, Lee CS, Park M, Song JH. Diclofenac inhibition of sodium currents in rat dorsal root ganglion neurons. Brain Res, 2003 Nov 28, 992(1): 120–7.Lin Y, Mather LE, Power I, Cousins MJ. The effect of diclofenac on the expression of spinal cord c–fos–like immunoreactivity after ischemia– reperfusion–induced acute hyperalgesia in the rat tail. Anesth Analg, 2000 May, 90(5): 1141–5.Lin Y, Mather LE, Power I, Cousins MJ. The effect of diclofenac on the expression of spinal cord c–fos–like immunoreactivity after ischemia– reperfusion–induced acute hyperalgesia in the rat tail. Anesth Analg, 2000 May, 90(5): 1141–5.Durigl T, Vitaus M, Pucar I, Mico M. Diclofenac sodium (Voltaren): Results of a multicenter comparative trial an adult-onset rheumatoid arthritis. J Int Med Res, 1975, 3: 139-144.Durigl T, Vitaus M, Pucar I, Mico M. Diclofenac sodium (Voltaren): Results of a multicenter comparative trial an adult-onset rheumatoid arthritis. J Int Med Res, 1975, 3: 139-144.Bijlsma A. The long-term efficacy and tolerability of Voltaren (diclofenac sodium) and indomethacin in rheumatoid arthritis. Scand J Rheumatol, 1978, 22: 74-80.Bijlsma A. The long-term efficacy and tolerability of Voltaren (diclofenac sodium) and indomethacin in rheumatoid arthritis. Scand J Rheumatol, 1978, 22: 74-80.Rossi FA, Baroni L. A double-blind comparison between diclofenac sodium and ibuprofen in osteoarthrit. J Int Med Res, 1975, (3): 267-269.Rossi FA, Baroni L. A double-blind comparison between diclofenac sodium and ibuprofen in osteoarthrit. J Int Med Res, 1975, (3): 267-269.Смоленский В.С., Крель А.А., Янкин В.В. и соавт. Клиническая оценка эффективности вольтарена у больных ревматоидным артритом в сравнении с аспирином с применением слепого перекрестного метода. Новые возможности клинического применения нестероидных противовоспалительных средств в ревматологии. Доклады, представленные на симпозиуме, проходившем 9 июня 1976 года в Москве, 59-69.Smolensky VS, Krel AA, Yankin VV, et al. Clinical evaluation of the efficacy of voltaren in patients with rheumatoid arthritis in comparison with aspirin using a blind cross method. New possibilities of the clinical use of non-steroidal anti-inflammatory drugs in rheumatology. The papers presented at the symposium held on June 9, 1976 in Moscow, 59-69.Чикколунги С.Н., Шубигер Б.И. Результаты клинических испытаний Вольтарена в различных странах. Новые возможности клинического применения нестероидных противовоспалительных средств в ревматологии. Доклады, представленные на симпозиуме, проходившем 9 июня 1976 года в Москве, 39-53.Chikolungi SN, Shubiger BI Results of the clinical trials of Voltaren in different countries. New possibilities of the clinical use of non-steroidal anti-inflammatory drugs in rheumatology. The papers presented at the symposium held on June 9, 1976 in Moscow, 39-53.Комаров Ф.И., Савельев А., Шатрова И.Л. и соавт. Вольтарен в лечении заболеваний суставов. Новые возможности клинического применения нестероидных противовоспалительных средств в ревматологии. Доклады, представленные на симпозиуме, проходившем 9 июня 1976 года в Москве, 71-77.Komarov FI, Saveliev A, Shatrova IL, et al. Voltaren in the treatment of joint diseases. New possibilities of the clinical use of non-steroidal anti-inflammatory drugs in rheumatology. The papers presented at the symposium held on June 9, 1976 in Moscow, 71-77.Крель А.А., Шехтер А.Б., Болотин Е.В. и соавт. Влияние вольтарена на некоторые лабораторные показатели активности ревматоидного артрита и морфологические проявления синовита. Новые возможности клинического применения нестероидных противовоспалительных средств в ревматологии. Доклады, представленные на симпозиуме, проходившем 9 июня 1976 года в Москве, 87-95Krel AA, Shekhter AB, Bolotin EV, et al. The effect of voltaren on some laboratory indicators of the rheumatoid arthritis activity and the morphological manifestations of synovitis. New possibilities of the clinical use of non-steroidal anti-inflammatory drugs in rheumatology. The papers presented at the symposium held on June 9, 1976 in Moscow, 87-95.Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med, 2004 Jul 15, 117(2): 100-6.Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med, 2004 Jul 15, 117(2): 100-6.Furst DE, Kolba KS, Fleischmann R. et.al. Dose response and safety study of meloxicam up to 22,5 mg daily in rheumatoid arthritis, a 12 week multicenter, double-blind, dose response study versus placebo and diclofenaс. J Rheum, 2002, 2: 436-446.Furst DE, Kolba KS, Fleischmann R. et.al. Dose response and safety study of meloxicam up to 22,5 mg daily in rheumatoid arthritis, a 12 week multicenter, double-blind, dose response study versus placebo and diclofenaс. J Rheum, 2002, 2: 436-446.Laine L, Curtis SP, Cryer B, et.al. Assessment of upper gastrointestinal safety of eterocoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Eterocoxib and Diclofenac Arthritis Long Term (MEDAL) programme: a randomised comparison. Lancet, 2007, 369: 465-473.Laine L, Curtis SP, Cryer B, et.al. Assessment of upper gastrointestinal safety of eterocoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Eterocoxib and Diclofenac Arthritis Long Term (MEDAL) programme: a randomised comparison. Lancet, 2007, 369: 465-473.Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of pros-tanoid formation transducing biochemical selectivity into clinical read-outs. J Clin Invest, 2001, 108: 7-13.Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of pros-tanoid formation transducing biochemical selectivity into clinical read-outs. J Clin Invest, 2001, 108: 7-13.Reilly IAG, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood, 1987, 69: 180-186.Reilly IAG, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood, 1987, 69: 180-186.Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunites. J Clin Invest, 2006, 116: 4-15.Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunites. J Clin Invest, 2006, 116: 4-15.Gatella-Lawson F, Reilly MP, Kapoor SC, et.al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med, 2001, 345: 1809-1817.Gatella-Lawson F, Reilly MP, Kapoor SC, et.al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med, 2001, 345: 1809-1817.Emery P, Zeidler H, Kiven KT, et.al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet, 1999, 354: 2106-2111.Emery P, Zeidler H, Kiven KT, et.al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet, 1999, 354: 2106-2111.Sikes DH, Agrawal NM, Zhao WW. et.al. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroent Hepat,Sikes DH, Agrawal NM, Zhao WW. et.al. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroent Hepat,Pavelka K, Recker DP, Verburg KM. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastrointestinal ulcers: results of a 26-week trial. Rheum (Oxford),2003, 42: 1207-1215.Pavelka K, Recker DP, Verburg KM. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastrointestinal ulcers: results of a 26-week trial. Rheum (Oxford),2003, 42: 1207-1215.Shiokawa Y, Takatori M, Sakuma A. Multi-center trial of Voltaren (GP 45,840) on rheumatoid arthritis bu double-blind technique. J Jap Rheum Ass, 1972, 12: 271-275.Shiokawa Y, Takatori M, Sakuma A. Multi-center trial of Voltaren (GP 45,840) on rheumatoid arthritis bu double-blind technique. J Jap Rheum Ass, 1972, 12: 271-275.Российские клинические рекомендации. Ревматология под редакцией академика РАН Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2017. 464 с.Russian clinical guidelines. Rheumatology edited by academician of the Russian Academy of Sciences Nasonov EL. Moscow: GEOTAR-Media, 2017. 464 p.Бадокин В.В. Нестероидные противовоспалительные препараты в локальной терапии ревматических заболеваний. Лечащий врач, 2010, (4): 72-74.Badokin VV. Non-steroidal anti-inflammatory drugs in local therapy for rheumatic diseases. Lechashchiy Vrach, 2010, (4): 72-74.Massey T, Derry S, Moore R, McQuay H. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev, 2010, 6: CD007402.Massey T, Derry S, Moore R, McQuay H. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev, 2010, 6: CD007402.Jorge L. Topical analgesics. Journal of Pain Research, 2011, 4: 11–24.Jorge L. Topical analgesics. Journal of Pain Research, 2011, 4: 11–24.Sintov AC, Botner S. Transdermal drug delivery using microemulsion and aqueous systems: influence of skin storage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems. Int J Pharm, 2006, 311(1-2): 55-62.Sintov AC, Botner S. Transdermal drug delivery using microemulsion and aqueous systems: influence of skin storage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems. Int J Pharm, 2006, 311(1-2): 55-62.Riess W, Schmid K, Botta L. et al. The percutaneous absorption of diclofenac. Arzneimittelforschung, 1986, 36(7): 1092-6.Riess W, Schmid K, Botta L. et al. The percutaneous absorption of diclofenac. Arzneimittelforschung, 1986, 36(7): 1092-6.Radermacher J, Jentsch D, Scholl MA, Lustinetz T, Frolich JC. Diclofenac concentra-tions in synovial fluid and plasma after cutaneous application in inflammatory and degenertive joint disease. Br J Clin Pharmacol, 1991, 31(5): 537-541.Radermacher J, Jentsch D, Scholl MA, Lustinetz T, Frolich JC. Diclofenac concentra-tions in synovial fluid and plasma after cutaneous application in inflammatory and degenertive joint disease. Br J Clin Pharmacol, 1991, 31(5): 537-541.Jondolph-Zink B, Gronwold U. Rheummatol, 1996, 6: 412-9.Jondolph-Zink B, Gronwold U. Rheummatol, 1996, 6: 412-9.Garcia-Miranda R. Treatment of musculo-skeletal lesions in athletes with a new topic antiinflamatory: diethylammonium diclofenac, comparative double-blind study. Compend invest clin Latinoam, 1987, 7(3): 9-24.Garcia-Miranda R. Treatment of musculo-skeletal lesions in athletes with a new topic antiinflamatory: diethylammonium diclofenac, comparative double-blind study. Compend invest clin Latinoam, 1987, 7(3): 9-24.Predel HG, Hamelsky S, Gold M, Giannetti B. Efficacy and safety of diclofenac diethylamine 2.32% gel in acute ankle sprain. Med Sci Sports Exerc, 201, 44(9): 1629-36. doi: 10.1249/ MSS.0b013e318257ed41.Predel HG, Hamelsky S, Gold M, Giannetti B. Efficacy and safety of diclofenac diethylamine 2.32% gel in acute ankle sprain. Med Sci Sports Exerc, 201, 44(9): 1629-36. doi: 10.1249/ MSS.0b013e318257ed41.Predel HG, Giannetti B, Pabst H, Schaefer A, Hug AM, Burnett I. Efficacy and safety of diclofenac diethylamine 1.16% gel in acute neck pain: a randomized, doubleblind, placebocon-trolled study. BMC Musculoskelet Disord, 2013, 14(1): 250. https: doi.org/10.1186/14712474-14-250.Predel HG, Giannetti B, Pabst H, Schaefer A, Hug AM, Burnett I. Efficacy and safety of diclofenac diethylamine 1.16% gel in acute neck pain: a randomized, doubleblind, placebocon-trolled study. BMC Musculoskelet Disord, 2013, 14(1): 250. https: doi.org/10.1186/14712474-14-250.González de Vega C, Speed C, Wolfarth B, González J. Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: A multicentre, randomised, blinded, controlled and non-inferiority trial. Int J Clin Pract, 2013, 67(10): 979-989. https: doi. org/10.1111/ijcp.12219.González de Vega C, Speed C, Wolfarth B, González J. Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: A multicentre, randomised, blinded, controlled and non-inferiority trial. Int J Clin Pract, 2013, 67(10): 979-989. https: doi. org/10.1111/ijcp.12219.Derry S, Moore RA, Gaskell H, McIntyre M, Wiffen PJ. Topical NSAIDs for acute musculo-skeletal pain in adults. Cochrane Database of Syst Rev, 2015, 6: CD007402. doi: 10.1002/14651858.CD007402.pub3.Derry S, Moore RA, Gaskell H, McIntyre M, Wiffen PJ. Topical NSAIDs for acute musculo-skeletal pain in adults. Cochrane Database of Syst Rev, 2015, 6: CD007402. doi: 10.1002/14651858.CD007402.pub3.Zacher J, Burger KJ, Farber L, Grave M, Abberger H, Bertsch K. Topisches Diclofenac Emulgel versus orales Ibuprofen in der Therapie der aktivierten Arthrose der Fingergelenke (Heberden- und/oder Bouchard-Arthrose). Akt Rheumatol, 2001, 26(1): 7-14. https: doi. org/10.1055/s-2001-11369.Zacher J, Burger KJ, Farber L, Grave M, Abberger H, Bertsch K. Topisches Diclofenac Emulgel versus orales Ibuprofen in der Therapie der aktivierten Arthrose der Fingergelenke (Heberden- und/oder Bouchard-Arthrose). Akt Rheumatol, 2001, 26(1): 7-14. https: doi. org/10.1055/s-2001-11369.Niethard FU, Gold MS, Solomon GS, Liu JM, Unkauf M, Albrecht HH, Elkik F. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol, 2005 Dec, 32(12): 2384-92.Niethard FU, Gold MS, Solomon GS, Liu JM, Unkauf M, Albrecht HH, Elkik F. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol, 2005 Dec, 32(12): 2384-92.Инструкция по применению лекарственного препарата для медицинского применения Вольтарена Эмульгеля. Гель для наружного применения 2%. Рег. № ЛП 002267-281116 от 28.11.2016 г. https: //www.rlsnet.ru/tn_index_ id_7427.htm.Patient Information Leaflet for a medicinal product for human use Voltaren Emulgel. Topical gel 2%. Reg. No. LP 002267-281116 dated 11/28/2016. Https: //www.rlsnet. ru/tn_index_ id_7427.htm

The authors declare that there are no conflicts of interest present.